Short answer
AbbVie Inc (ABBV) filed its fiscal 2025 10-K annual report with the SEC on Feb 20, 2026. It reported revenue of $61.2B (+8.6% year over year) and net income of $4.2B.
- Top risk flagged: FDA approval and EC marketing authorization for Rinvoq in 2025 for giant cell arteritis and ulcerative colitis, supporting U.S. exclusivity through April 2037
FY2025 key financial metrics · XBRL
- Revenue
- $61.2B
- +8.6% YoY
- Net income
- $4.2B
- −1.2% YoY
- Operating margin
- 24.6%
- +8.4 pp YoY
- Gross margin
- 19.7%
- +0.7 pp YoY
- EPS (diluted)
- $2.36
- −1.3% YoY
- ROE
- -129.2%
- −257.9 pp YoY
- Operating cash flow
- $19.0B
- +1.2% YoY
Source: XBRL data from the AbbVie Inc (ABBV) FY2025 10-K on SEC EDGAR. USD.
AbbVie Inc FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: global biopharmaceutical company focused on innovative therapies in immunology, neuroscience, oncology, aesthetics, and eye care
- New emphasis: expanded indications and geographic approvals for Skyrizi and Rinvoq across autoimmune diseases, plus new oncology ADC Epkinly approved for lymphoma
- Strategic shift: single global business segment operating model aligned for unified resource allocation and long-term strategic goal achievement
- Quantitative highlight: 2025 gross revenues in U.S. distributed mostly through three wholesalers, none exceeding 43% share
- Noteworthy fact: continued biosimilar competition pressure on Humira globally, with evolving FDA regulatory pathway and complex approval process
Management Discussion & Analysis
- Revenue $61.2B, up 9% YoY on reported and constant currency basis
- Operating earnings $15.1B, operating margin approximately 24.7% (15.1B/61.2B)
- Best segment: not explicitly broken down; costs include $7.4B amortization, $6.5B contingent liabilities fair value change
- Cash flow from operations $19.0B, no disclosed buybacks or dividends, ongoing investment in pipeline and brands
- Forward outlook: $100B pledged for US R&D/capex over decade, tariff exemption for 3 years, risk of revenue erosion from Medicare price controls starting 2026
Risk Factors
- FDA approval and EC marketing authorization for Rinvoq in 2025 for giant cell arteritis and ulcerative colitis, supporting U.S. exclusivity through April 2037
- Global minimum tax "Pillar Two" implementation starting 2024 raising future income tax expense uncertainty under OECD rules
- Capital investment including new U.S. API facility in Illinois and biologics expansion in Massachusetts increases operational complexity and execution risk
- Biosimilar competition driving Humira U.S. net revenues down 57% in 2025 threatens market position and revenue stability
- $6.5B contingent consideration liabilities fair value increase in 2025 linked to Skyrizi sales projections creating significant financial risk exposure
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.